[1] KANTH P,INADOMI J M.Screening and prevention of colorectal cancer[J].BMJ, 2021(374):n1855. [2] 中华人民共和国国家卫生健康委员会.中国结直肠癌诊疗规范(2020年版)[J].中华外科杂志,2020,58(8):561-585. [3] FENG Z,CAO J,NIE Y,et al.Analysis of population-based colorectal cancer screening in Guangzhou,2011-2015[J].Cancer Med,2019,8(5):2496-2502. [4] SHAUKAT A,LEVIN T R.Current and future colorectal cancer screening strategies[J].Nat Rev Gastroenterol Hepatol,2022,19(8):521-531. [5] CHIU H M,CHEN S L,YEN A M,et al.Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program[J].Cancer,2015,121(18):3221-3229. [6] ALLISON J E,TEKAWA I S,RANSOM L J,et al.A comparison of fecal occult-blood tests for colorectal-cancer screening[J].N Engl J Med,1996,334(3):155-160. [7] LEE J K,LILES E G,BENT S,et al.Accuracy of fecal immunochemical tests for colorectal cancer:Systematic review and meta-analysis[J].Ann Intern Med,2014,160(3):171. [8] 国家消化系统疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,中华医学会消化内镜学分会,等.中国早期结直肠癌筛查流程专家共识意见(2019,上海)[J].中华消化内镜杂志,2019,36(10):709-719. [9] 陈万青,李霓,兰平,等.中国结直肠癌筛查与早诊早治指南(2020,北京)[J].中国肿瘤,2021,30(1):1-28. [10] MARCUELLO M,VYMETALKOVA V,NEVES RPL,et al.Circulating biomarkers for early detection and clinical management of colorectal cancer[J].Mol Aspects Med,2019(69):107-122. [11] VANHAESEBROECK B,BILANGES B,MADSEN R R,et al.Perspective:Potential impact and therapeutic implications of oncogenic PI3K activation on chromosomal instability[J].Biomolecules,2019,9(8):331. [12] LUO H,ZHAO Q,WEI W,et al.Circulating tumor DNA methylation profiles enable early diagnosis,prognosis prediction,and screening for colorectal cancer[J].Sci Transl Med,2020,12(524):eaax7533. [13] BETTEGOWDA C,SAUSEN M,LEARY R J,et al.Detection of circulating tumor DNA in early- and late-stage human malignancies[J].Sci Transl Med,2014,6(224):224ra24. [14] KALIMUTHO M,DEL VECCHIO BLANCO G,DI CECILIA S,et al.Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer[J].J Gastroenterol,2011,46(12):1391-1402. [15] JUNG G,HERNÁNDEZ-ILLÁN E,MOREIRA L,et al.Epigenetics of colorectal cancer:Biomarker and therapeutic potential[J].Nat Rev Gastroenterol Hepatol,2020,17(2):111-130. [16] HENRIKSEN T V,TARAZONA N,FRYDENDAHL A,et al.Circulating tumor DNA in stage III colorectal cancer,beyond minimal residual disease detection,toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences[J].Clin Cancer Res,2022,28(3):507-517. [17] RACILA E,EUHUS D,WEISS A J,et al.Detection and characterization of carcinoma cells in the blood[J].Proc Natl Acad Sci USA,1998,95(8):4589-4594. [18] MARCUELLO M,DURAN-SANCHON S,MORENO L,et al.Analysis of A 6-mirna signature in serum from colorectal cancer screening participants as non-invasive biomarkers for advanced adenoma and colorectal cancer detection[J].Cancers,2019,11(10):1542. [19] ZAPKA J,KLABUNDE C N,TAPLIN S,et al.Screening colonoscopy in the US:Attitudes and practices of primary care physicians[J].J Gen Intern Med,2012,27(9):1150-1158. [20] BAXTER N N,WARREN J L,BARRETT M J,et al.Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty[J].J Clin Oncol,2012,30(21):2664-2669. [21] LADABAUM U,DOMINITZ J A,KAHI C,et al.Strategies for colorectal cancer screening[J].Gastroenterology,2020,158(2):418-432. [22] SCHOEN R E,PINSKY P F,WEISSFELD J L,et al.Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy[J].N Engl J Med,2012,366(25):2345-2357. [23] NERAD E,LAHAYE M J,MAAS M,et al.Diagnostic accuracy of CT for local staging of colon cancer:A systematic review and meta-analysis[J].Am J Roentgenol Am J Roentgenol,2016,207(5):984-995. [24] HUANG Y,LIANG C,HE L,et al.Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer[J].J Clin Oncol,2016,34(18):2157-2164. [25] CHEN L D,LIANG J Y,WU H,et al.Multiparametric radiomics improve prediction of lymph node metastasis of rectal cancer compared with conventional radiomics[J].Life Sci,2018(208):55-63. [26] 杨艳红,严超贵,何洁珺,等.二种直肠充盈方法对直肠癌高分辨率MRI检查图像质量的探讨[J].中华消化病与影像杂志(电子版),2017,7(6):257-260. [27] JIA H,JIANG X,ZHANG K,et al.A nomogram of combining IVIM-DWI and MRI radiomics from the primary lesion of rectal adenocarcinoma to assess nonenlarged lymph node metastasis preoperatively[J].J Magn Reson Imaging,2022,56(3):658-667. [28] LIU Y,WAN L,PENG W,et al.A magnetic resonance imaging(MRI)-based nomogram for predicting lymph node metastasis in rectal cancer:A node-for-node comparative study of MRI and histopathology[J].Quant Imaging Med Surg,2021,11(6):2586-2597. [29] MIRSHAHVALAD S A,HINZPETER R,KOHAN A,et al.Diagnostic performance of[18F]-FDG PET/MR in evaluating colorectal cancer:A systematic review and meta-analysis[J].Eur J Nucl Med Mol Imaging,2022,49(12):4205-4217. [30] PENG B,LU J,WU Z,et al.Intersphincteric resection versus abdominoperineal resection for low rectal cancer:A meta-analysis[J].Surg Innov,2020,27(4):392-401. [31] HE Z,PENG B,CHEN W,et al.Clinical efficacy of intersphincteric resection for low rectal cancer compared with abdominoperineal resection:A single-center retrospective study[J].Am Surg,2023,89(4):1009-1017. [32] LIU H,ZENG Z,ZHANG H,et al.Morbidity,mortality,and pathologic outcomes of transanal versus laparoscopic total mesorectal excision for rectal cancer short-term outcomes from a multicenter randomized controlled trial[J].Ann Surg,2023,277(1):1-6. [33] LI W,DONG B,PENG B,et al.Glove single-port laparoscopy-assisted transanal total mesorectal excision for low rectal cancer:a preliminary report[J].World J Surg Oncol,2019,17(1):202. [34] YANG W F,CHEN W,HE Z,et al.Simple transanal total mesorectal resection versus laparoscopic transabdominal total mesorectal resection for the treatment of low rectal cancer:A single-center retrospective case-control study[J].Front Surg,2023(10):1171382. [35] DENG Y,CHI P,LAN P,et al.Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer:Final results of the Chinese FOWARC trial[J].J Clin Oncol,2019,37(34):3223-3233. [36] SCHRAG D,SHI Q,WEISER M R,et al.Preoperative treatment of locally advanced rectal cancer[J].N Engl J Med,2023,389(4):322-334. [37] PRAGER G W,TAIEB J,FAKIH M,et al.Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer[J].N Engl J Med,2023,388(18):1657-1667. [38] 顾艳宏,姜争,李健,等.结直肠癌靶向治疗中国专家共识[J].中华普通外科学文献(电子版),2023,17(1):1-8. [39] DASARI A,LONARDI S,GARCIA-CARBONERO R,et al.Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer(FRESCO-2):An international,multicentre,randomised,double-blind,phase 3 study[J].Lancet,2023,402(10395):41-53. [40] YAEGER R,WEISS J,PELSTER M S,et al.Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C[J].N Engl J Med,2023,388(1):44-54. [41] LIPSON E J,SHARFMAN W H,DRAKE C G,et al.Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody[J].Clin Cancer Res,2013,19(2):462-468. [42] CERCEK A,LUMISH M A,SINOPOLI J C,et al.Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer[J].J Clin Oncol,2022,40(17_suppl):LBA5. [43] CERCEK A,LUMISH M,SINOPOLI J,et al.PD-1 blockade in mismatch repair-deficient,locally advanced rectal cancer[J].New Engl J Med,2022,386(25):2363-2376. [44] WANG Q X,XIAO B Y,CHENG Y,et al.Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer:A multicentre cohort study[J].Eur J Cancer,2022(174):176-184. [45] CHEN G,JIN Y,GUAN W L,et al.Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient,locally advanced rectal cancer:An open-label,single-centre phase 2 study[J].Lancet Gastroenterol Hepatol,2023,8(5):422-431. [46] WANG Y J,FLETCHER R,YU J,et al.Immunogenic effects of chemotherapy-induced tumor cell death[J].Genes Dis,2018,5(3):194-203. [47] WEN L,TONG F,ZHANG R,et al.The research progress of PD-1/PD-L1 inhibitors enhancing radiotherapy efficacy[J].Front Oncol,2021(11):799957. [48] YANG Z,WU G,ZHANG X,et al.Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer[J].Front Immunol,2022(13):1001444. |